Rational Design of a Live Attenuated Dengue Vaccine: 2’-O-Methyltransferase Mutants Are Highly Attenuated and Immunogenic in Mice and Macaques

Roland Züst1*, Hongping Dong2, Xiaofeng Li3, David C. Chang2, Bo Zhang4, Thavamalar Balakrishnan1, Ying-Xiu Toh1, Tao Jiang3, Shi-Hua Li3, Yong-Qiang Deng3, Brett R. Ellis5, Esther M. Ellis5, Michael Poidinger1, Francesca Zolezzi1, Cheng-Feng Qin3, Pei-Yong Shi2,6, Katja Fink1*

1 Singapore Immunology Network, Agency for Science, Technology and Research, Singapore, 2 Novartis Institute for Tropical Diseases, Singapore, 3 State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China, 4 State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China, 5 Duke Graduate Medical School, Singapore, 6 Wadsworth Center, New York State Department of Health, Albany, New York, United States of America

Abstract

Dengue virus is transmitted by Aedes mosquitoes and infects at least 100 million people every year. Progressive urbanization in Asia and South-Central America and the geographic expansion of Aedes mosquito habitats have accelerated the global spread of dengue, resulting in a continuously increasing number of cases. A cost-effective, safe vaccine conferring protection with ideally a single injection could stop dengue transmission. Current vaccine candidates require several booster injections or do not provide protection against all four serotypes. Here we demonstrate that dengue virus mutants lacking 2’-O-methyltransferase activity are highly sensitive to type I IFN inhibition. The mutant viruses are attenuated in mice and rhesus monkeys and elicit a strong adaptive immune response. Monkeys immunized with a single dose of 2’-O-methyltransferase mutant virus showed 100% sero-conversion even when a dose as low as 1,000 plaque forming units was administrated. Animals were fully protected against a homologous challenge. Furthermore, mosquitoes feeding on blood containing the mutant virus were not infected, whereas those feeding on blood containing wild-type virus were infected and thus able to transmit it. These results show the potential of 2’-O-methyltransferase mutant virus as a safe, rationally designed dengue vaccine that restrains itself due to the increased susceptibility to the host’s innate immune response.

Citation: Züst R, Dong H, Li X-F, Chang DC, Zhang B, et al. (2013) Rational Design of a Live Attenuated Dengue Vaccine: 2’-O-Methyltransferase Mutants Are Highly Attenuated and Immunogenic in Mice and Macaques. PLoS Pathog 9(8): e1003521. doi:10.1371/journal.ppat.1003521

Editor: Michael Gale Jr., University of Washington, United States of America

Received October 8, 2012; Accepted June 10, 2013; Published August 1, 2013

Copyright: © 2013 Züst et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: KF’s group was supported by the Agency for Science, Technology and Research, Singapore. BZ’s group was supported by the National Basic Research Program of China (2012CB518904) and the National Natural Science Foundation of China (31170158). CFQ’s group was supported by the National Basic Research Program of China (2012CB518904) and the National Natural Science Foundation of China (31270974). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: We have read the journal’s policy and have the following conflicts: HD, DC and PYS are currently or have been under the employment of Novartis, which provided funds and equipment to conduct the studies and where they receive salary, benefits and stock. This does not alter our adherence to all PLoS Pathogens policies on sharing data and materials.

* E-mail: qincf@bmi.ac.cn (CFQ); pei_yong.shi@novartis.com (PYS); Katja_Fink@immunol.a-star.edu.sg (KF)

† These authors contributed equally to this work.

Introduction

Dengue virus (DENV) is a member of the Flaviviridae family. DENV infection causes dengue fever (DF) and the more severe forms of the disease, dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). DENV has four serotypes (DENV-1 to -4), each of which is capable of causing severe disease. The frequency, severity, and geographical spread of cases have increased over the past decades [1,2]. Every year, one hundred million new cases of DF and 250,000 DHF/DSS are estimated by the WHO. At present, despite intensive global research efforts, no vaccine or antiviral treatment for dengue infection is available. Vaccine development is complex due to multiple factors. (i) An effective vaccine must consist of a tetravalent formulation protecting against each of the four serotypes because more than one serotype typically circulates in a region. (ii) A sub-protective vaccine potentially increases the risk of vaccines to develop the more severe forms of dengue during repeated infection because of a known association of pre-existing immunity with severity [3,4]. (iii) Since most infections occur in developing countries, an ideal vaccine should be affordable and fully protective [5]. Taken together, a vaccine inducing a robust level of immunity ideally with only one inoculation is required.

Live-attenuated vaccines are replication-competent viruses, which can induce an immune response and an immune memory that are comparable to those induced by the wild-type virus. Live-attenuated viruses do not cause disease because of the low level of replication and hence low levels of inflammation. Prominent examples of successful live-attenuated vaccines providing long-term immunity are those against vaccinia virus, poliovirus (Sabin), and two members of the Flaviviridae family, yellow fever virus (YF-17D) and Japanese encephalitis virus (JEV SA14-14-2) [6]. Live-attenuated DENV vaccines have been shown to induce protective neutralizing antibody titers in mice, monkeys, and humans [7–9]. In
Author Summary

The four serotypes of dengue virus cause severe outbreaks globally in tropical countries with thousands of patients requiring hospitalization. The health care and indirect economic cost of dengue in endemic countries is huge. Despite this, no clinically approved vaccine or antiviral treatment is currently available. Dengue transmission could be stopped with a vaccine that provides full protection to all serotypes. Dengue afflicts many developing countries and a vaccine should therefore be cost-effective and should provide protection with ideally a single injection. Here we present a novel dengue vaccine approach that harbours mutation(s) in the 2'-O-methyltransferase (MTase), a viral enzyme that methylates viral RNA as a strategy to escape the host immune response. Non-methylated RNA is recognized as “foreign” and triggers an interferon response in the cell. The MTase mutant virus is immediately recognized by the host’s immune response and hardly has a chance to spread in the organism while an immune response is efficiently triggered by the initially infected cells. Mice and monkeys infected with the mutant virus developed an immune response that fully protected them from a challenge with wild-type virus. Furthermore, we show that MTase mutant dengue virus cannot infect Aedes mosquitoes. Collectively, the results suggest 2’-O-MTase mutant dengue virus as a safe, highly immunogenic vaccine approach.

Addition, evidence that a balanced T cell response contributes to protection is accumulating, emphasizing the importance of T cell epitopes in a vaccine [8].

Flaviviruses are positive-sense, single-stranded RNA viruses. The flavivirus genome encodes for 3 structural (C, prM, and E) and 7 non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5). NS3 is a multifunctional protein, consisting of the RNA-dependent RNA polymerase [10] and methyltransferase (MTase) activities responsible for 5’ RNA cap formation [11,12] as well as internal RNA methylation [13]. While N-7-methylation is essential for RNA translation and stability, the function of 2’-O-methylation has remained elusive until recently. We and others demonstrated that while 2’-O-MTase is not essential for viral replication in vitro, viruses bearing mutations in the highly conserved MTase catalytic K-D-K-E tetrad are severely attenuated in the host due to the inability of the virus to shield viral RNA from recognition by host innate immune factors [14,15]. DENV RNA binds to RIG-I and MDA5 [16,17], which activates interferon (IFN)-β production via a cascade involving IFN-β promoter stimulator 1 (IPS-1) [17]. IFNs in turn activate IFN stimulated genes (ISGs), which induce antiviral responses in infected and neighbouring cells. IFN-induced proteins with tetratricopeptide repeats (IFITs) are critical for the inhibition of viral infections, although their functions are only partially understood [14,18]. The human IFIT gene family comprises four members: IFIT1, IFIT2, IFIT3 (= IFIT4), and IFIT5; whereas mice only express IFIT1, 2 and 3 [19]. Interestingly, IFIT homologs are conserved from amphibians to mammals, suggesting that they play a central role in the innate immune response [19]. IFIT1 and 2 bind to eukaryotic Initiation Factor 3 (eIF3) and inhibit translation [20], whereas IFIT3 amplifies the antiviral signal by connecting IPS-1 and TBK1, resulting in more IFN production [21]. The role of human IFIT5 is less well understood.

Here we demonstrate that DENV strains bearing a mutation in the catalytic site of the 2’-O-MTase replicated to high titres in cell culture whereas these mutant viruses were highly attenuated in mice and rhesus monkeys. The mutation was stable over several passages and reversion to wild-type (WT) was not observed. For further safety improvement, a second mutation in the 2’-O-MTase catalytic tetrad was introduced without affecting the viability of the virus in vitro. A single dose administration to rhesus macaques (RM) conferred protection to homologous DENV challenge. Mice immunized with a single dose of a divalent (DENV-1/2) formulation of the mutant viruses and mice immunized with the monovalent formulation showed comparable antibody responses, demonstrating that there was no interference between two serotypes of the DENV MTase mutants. Moreover, no enhanced infection and increased TNF-α levels were observed in immunized mice upon challenge with heterologous virus. Overexpression of IFIT5 in HEK-DC-SIGN cells suggested a role for IFIT1 in the attenuation of MTase mutant in human cells. Taken together, these results demonstrate the potential of 2’-O-MTase mutants as a DENV vaccine. To our knowledge, this is the first live-attenuated rational vaccine approach, tailored to optimally activate the innate and adaptive immune response while being severely attenuated due to its susceptibility to the IFN response.

Results

N7- and 2’-O-methylation activities of WT and mutant DENV-1 and -2

Flaviviruses replicate in the cytoplasm. The cytoplasm-replicating viruses have evolved N7- and 2’-O-methyltransferases (MTase) to methylate their viral mRNA 5’ cap structures [22]. We have previously shown for West Nile virus (WNV) and DENV-1 that mutation of the Asp of the tetrad K-D-K-E completely abolished both N7- and 2’-O-MTase activities and was lethal for viral replication; mutations of the other three residues of the tetrad abolished 2’-O-methylation (with a decrease in N7-methylation), and led to attenuated viruses [14,23]. Since there are four serotypes of DENV, we introduced the same MTase mutations into DENV-2 to examine whether the same approach was feasible with more than one serotype. A WT recombinant MTase, representing the N-terminal 296 amino acids of the DENV-2 NS5 (strain TSV01), was cloned and expressed. Two mutant MTases containing Ala-substitutions at the K-D-K-E tetrad (Fig. 1A) were prepared: one with a single E217A mutation and another with double K61A+E217A mutations. The mutant enzymes retained 95% and 77% of the WT N7-methylation activity, respectively; neither mutant exhibited any 2’-O-methylation activity (Fig. 1B). BHK-21 cells transfected with equal amounts of WT and mutant (E217A and K61A+E217A) genome-length RNAs of DENV-2 generated equivalent numbers of viral E protein-expressing cells (Fig. 1C). Both WT and mutant RNAs produced infectious viruses (passage 0) with similar plaque morphologies (Fig. 1D). The replication of mutant viruses was attenuated in mammalian Vero and mosquito C3/6 cells (Fig. 1E). Continuous culturing of the mutant viruses on Vero cells or HEK-293 cells expressing DC-SIGN (HEK-DC-SIGN) for ten rounds (3–4 days per round) did not change their plaque morphologies (Fig. 1D and data not shown). The expression of DC-SIGN facilitates DENV infection [24]. Sequencing of the passaged 0 and 10 viruses from both Vero and HEK-DC-SIGN cells showed that the engineered mutations were retained (Supplementary Fig. S1a and S1b). Similar results were obtained for DENV-1 containing the E216A (E216 in DENV-1 MTase is equivalent to E217 in DENV-2 MTase) or K61A+E216A mutation in MTase (Supplementary Fig. S2). Collectively, the results demonstrate that the 2’-O-MTase mutant DENV-1 and -2 are slightly attenuated, but stable in cell culture.
DENV 2′-O-MTase mutants are attenuated in mice and induce a protective immune response

We infected AG129 mice with the WT and 2′-O-MTase mutants (called “E216A” for DENV-1 and “E217A” for DENV-2 from this point) to assess viral replication and immunogenicity in vivo. AG129 mice lack the receptors for type I and type II IFNs, and have been used widely for antiviral and vaccine testing [25–28]. Mice were intraperitoneally (i.p.) infected with 2.75 × 10⁵ plaque-forming unit (PFU) of WT or mutant viruses. The viremia result showed that mutating K61A or E216A in DENV-1 and mutating E217A in DENV-2 attenuated the virus compared to the WT virus (Fig. 2A and B).

Next, we examined a combination of two MTase mutants (E216A and E217A) representing DENV-1 and DENV-2 to address a potential competition effect that has been described previously with attenuated strains in humans [29] and in mice [25]. To this end, mice were injected i.p. with 2.75 × 10⁵ PFU of E216A or E217A or a combination of both (a total of 5.5 × 10⁵ PFU viruses). At 30 days post immunization, mice were challenged i.p. with 1 × 10⁶ PFU of WT DENV-1 or 5 × 10⁶ PFU WT DENV-2. DENV specific IgG titers and viremia were observed. All mice immunized with E216A or E217A were protected against homologous challenge (Fig. 2C), demonstrating that the immune response was protective even though the IgG titers in E216A and/or E217A-infected mice were 2 to 10 times lower than those in the WT virus-infected mice (Fig. 2D and E).

A general concern for live attenuated vaccines is their theoretical potential to mutate back to WT under pressure of the immune system. To address this in our system, virus from mice infected with mutant DENV1 or DENV2 was isolated at day 3 after infection and the mutations were found to be stable (Supplementary Fig. S1c). To rule out that compensatory mutations were introduced into the viral genome, the input and output (day 3 after infection) virus was sequenced using Illumina deep sequencing technology. As summarized in Supplementary Table S1, only the single nucleotide polymorphisms (SNPs) responsible for the E216A or E217A mutation were found when comparing the sequences to wild-type DENV-1 or -2, respectively.

We next compared the neutralization and infection enhancing capacity of serum collected 30 days post immunization (Table 1 and Supplementary Fig. S3) [30]. Mutant viruses cause the same or less antibody-dependent enhancement (ADE) than the respective wild-type viruses in the heterologous setting (0.51 ± 0.16 vs. 0.74 ± 0.2 for DENV-1 immunization and ADE tested against DENV-2 and 0.64 ± 0.22 vs. 0.62 ± 0.14 for DENV-2 immunization and ADE tested against DENV-1) (Table 1). More importantly, we did not observe enhanced infection in vivo (Fig. 2C and see later challenge experiments with a virulent DENV-2 strain). These data suggest that vaccination with the E216A/E217A mutants does not cause ADE during heterologous challenge even though lower neutralizing Ab titers are generated by the mutant strains compared to the wild-type virus.
Vaccinated mice generate a non-structural protein-specific CD8 T cell response

While antibodies are crucial to reduce the viral load by binding and neutralizing virus particles, T cells are necessary for efficient viral clearance [31,32]. AG129 mice are not suitable to study T cell responses because of their lack of IFN-γ signaling, which is critical to activate T cells. We therefore used IFNAR mice lacking the receptor for IFN-α/β [33]. IFNAR mice were immunized with $2.75 \times 10^6$ PFU DENV-2 WT, DENV-2 E217A (strain TSV01) alone or in combination with DENV-1 E216A ($2.75 \times 10^6$ PFU DENV-1 E216A plus $2.75 \times 10^6$ PFU DENV-2 E217A). Blood was taken at indicated time points and viral titers were measured by real-time PCR. (C) Viral titers in the plasma of mice immunized with 2'-O-MTase mutant and challenged as indicated. Numbers in gray boxes indicate WT virus, whereas numbers in white boxes indicate 2'-O-MTase mutant virus. Mice were immunized i.p. with $2.75 \times 10^6$ PFU of the indicated 2'-O-MTase mutant serotype and challenged 30 days later with $5 \times 10^6$ PFU WT DENV-1 strain (strain 05K3126 used for challenge due to its high virulence in mice, unpublished data) or $3 \times 10^6$ PFU WT DENV-2. Blood was taken at indicated time points post challenge and IgG antibody titers against DENV-1 (D) and DENV-2 (E) were measured by ELISA. Data are representative of two experiments with three to four mice per group in each experiment (A, B) or two pooled experiments (C–E) with a total of 9 mice per group. Bars represent means with SEM (B–E).

DOI: 10.1371/journal.ppat.1003521.g002

Vaccinated mice are protected against challenge with the virulent DENV-2 strain

DENV-1 strain 05K3126 and DENV-2 strain TSV01 do not cause pathology in mice. To test for protection against a more virulent strain we immunized mice with DENV-1 E216A, DENV-2 E217A, a mixture of E216A and E217A, WT DENV-1 (Westpac) or WT DENV-2 (TSV01) or PBS and challenged them with the virulent DENV-2 strain D2Y98P [34] 30 days later (Fig. 4). DENV-2 E217A protected against the homologous challenge (Fig. 4A). Immunization with DENV-1 E216A protected 70% of the mice, showing limited cross-protection after infection with D2Y98P (Fig. 4A and 4B). No enhanced disease was detected after heterologous challenge. Increased TNF-α levels were associated
with pathology in the AG129 mouse model in the context of
ADE [35]. To further assess the possibility of ADE-associated
pathology, we measured TNF-α levels in plasma three days after
challenge. High levels of TNF-α were only detected in unimmu-
nized (PBS) mice, showing that TNF-α as a marker of pathology
was independent of ADE, and that immunization with E216A did
not cause ADE after heterologous challenge. These data demon-
strate that immunization with E217A protects mice against
challenge with an aggressive, virulent DENV-2 strain that causes
100% mortality in unimmunized mice.

DENV 2'-O-MTase mutants are highly attenuated
in macaques and induce a broad and protective immune
response

To assess the safety (viremia profile) and efficacy (neutralizing anti-
body response and protection against challenge) of the 2'-O-MTase
mutant DENV vaccine approach in an immunologically competent
host, three groups of Rhesus monkeys (RM) were immunized with
different doses of E217A. One group received a low dose
(1 × 10^3 PFU), one group a medium dose (1 × 10^4 PFU), and one
group a high dose (1 × 10^5 PFU) of E217A virus. Viremia was
monitored during 10 days after inoculation. The E217A virus was
severely attenuated, and no viremia was detected except for one
animal (R0105) that had received a high dose (1 × 10^5 PFU) and
developed a low viremia (Table 2). Virus was extracted for sequenc-
ing, and it was confirmed that the E217A mutation was retained in
the virus extracted at days 3, 4 and 7 from this animal. Importantly,
full virus genome sequencing of the viral RNA recovered at day 7
showed that no compensatory mutations were introduced (data not
shown). All immunized monkeys developed neutralizing antibodies
to DENV-2 on day 15 after immunization (Table 3). ADE was
analyzed in a K562 assay and a similar enhancement pattern was

| Table 1. Neutralization and antibody-dependent enhancement of infection (ADE) in immunized AG129 mice. |
|---------------------------------|---------------------------------|---------------------------------|
| **Immunization:**               | **NT50 (mean fold dilution ±SD)** | **Max. ADE (mean fold dilution ±SD)** |
|---------------------------------|---------------------------------|---------------------------------|
|                                 | DENV-1 p | DENV-2 p | DENV-1 p | DENV-2 p |
| DENV-1 E216A                    | 252±59   | 388±153  | #        | 0.75±0.27 | 0.51±0.16 | # |
| DENV-1                          | 509±307  | *        | 556±107  | 0.98±0.5  | *        | 0.74±0.2  |
| DENV-2 E217A                    | 197±188  | 1035±557 | *        | 0.64±0.22 | 1.02±0.22 | * |
| DENV-2                          | 268±118  | 1548±566 | *        | 0.62±0.14 | 1.27±0.29 | * |
| DENV-1 E216A+DENV-2 E217A       | 202±78   | 655±261  | *        | 0.94±0.017| 1.05±0.32 | * |
| PBS                             | 88±66    | 251±228  | 0.18±0.01| 0.08±0.01 |

NT50 values are means ±SD of six to seven mice from two independent experiments.
Max. ADE values are normalized against 4G2, which was used as an internal standard for infection efficiency per experiment. Values are means ±SD from six to seven mice from two independent experiments.
Kruskal Wallis test with multiple comparisons:
*: p<0.05 compared to PBS.
**: p<0.05 compared to DENV-2.
doi:10.1371/journal.ppat.1003521.t001

Figure 3. T cell IFN-γ production elicited by 2'-O-MTase mutant DENV-2. Splenocytes of IFNAR mice infected with DENV-2 E217A or DENV-2 WT were harvested at day 7 and were re-stimulated with DENV-2 or with peptides for the quantification of IFN-γ production in CD4 and CD8 cells. (A) Intracellular IFN-γ was measured in spleen CD4 and CD8 cells (lymphocyte gate, viable cells, cell duplets excluded) of non-immunized or immunized mice; representative graphs for each group are shown. (B) Quantitative analysis of IFN-γ production. Bars are means±SEM from two independent experiments with 2–3 mice per group in each experiment. P value was determined with an unpaired students t test.
doi:10.1371/journal.ppat.1003521.g003
observed for both heterologous and homologous infection in vitro: ADE correlated with the neutralizing titer, i.e., the higher the NT50 the higher the enhancement (Supplementary Fig. S4). This argues against a physiologically relevant infection enhancement, which would only be expected after heterologous infection. By day 30 after immunization, all monkeys including the ones with low dose immunization developed high titers (GMT $92) of neutralizing antibodies (Table 3). The monkeys were then challenged with $1 \times 10^5$ PFU of WT DENV-2 on day 64 post-immunization. No viremia was detected in all immunized monkeys, whereas all four PBS-immunized controls had a mean peak virus titer of $2.5 \log_{10}$ PFU/ml and mean viremia duration of 4.8 days (Table 4). In all animals except one (R0055), anamnestic antibody responses were observed after challenge (Table 3). These data demonstrate that live, attenuated DENV MTase mutant virus, even when administered at low dose ($1 \times 10^3$ PFU), can induce protective immunity in non-human primates.

IFN-β pre-treatment inhibits 2′-O-MTase mutant infection with the involvement of IFIT1

The 2′-O-methylation of the 5′ cap of WNV and coronavirus RNA functions to subvert innate host antiviral response through escape of IFIT-mediated suppression [14,15]. To assess whether this is true for DENV as well, we pretreated HEK-DC-SIGN cells with an increasing dose of IFN-β for 24 h. While HEK-DC-SIGN cells are susceptible to type I IFN, they do not produce detectable levels of IFN-β after infection with mutant or WT virus (data not shown). The IFN-β-treated cells were infected with WT or mutant E217A DENV-2. The E217A virus was significantly more sensitive to IFN-β pretreatment than the WT virus, as demonstrated by the percentage of infected cells (Fig. 5A) as well as the viral titers in culture supernatants (Fig. 5B). To test the stability of the mutation under IFN pressure and in different cell types we passaged the virus in the presence of 0, 20 and 200 U/ml IFN-β in HEK-DC-SIGN and U937-DC-SIGN. As illustrated in Supplementary Fig. S5,

**Table 2.** Viremia in RMs immunized with different doses of DENV-2 E217A.

| E217A dose (log10 PFU) | Monkey | Gender | Viremia (log10 PFU/ml) at indicated day post immunization | Mean Peak titer (SD) | Duration days |
|------------------------|--------|--------|----------------------------------------------------------|---------------------|---------------|
|                        |        |        | 1  2  3  4  5  6  7  8  9  10                          |                     |               |
| 5.0                    | R0319  | M      | 0  0  0  0  0  0  0  0  0  0                             | 0.4 (0.8)          | 0.8           |
| 5.0                    | R0212  | F      | 0  0  0  0  0  0  0  0  0  0                             |                     |               |
| 5.0                    | R0105  | M      | 0  0  1.5 1.6 0  0  0  0  0  0                             |                     |               |
| 5.0                    | R0942  | F      | 0  0  0  0  0  0  0  0  0  0                             |                     |               |
| 4.0                    | R0055  | M      | 0  0  0  0  0  0  0  0  0  0                             | 0  0               |               |
| 4.0                    | R0482  | F      | 0  0  0  0  0  0  0  0  0  0                             |                     |               |
| 4.0                    | R0098  | F      | 0  0  0  0  0  0  0  0  0  0                             |                     |               |
| 3.0                    | R0198  | F      | 0  0  0  0  0  0  0  0  0  0                             |                     |               |
| 3.0                    | R0195  | M      | 0  0  0  0  0  0  0  0  0  0                             |                     |               |

doi:10.1371/journal.ppat.1003521.t002
E217A was lost in the presence of IFN, whereas wild-type virus resisted the IFN pressure in both cell lines. E217A isolated from passage three in HEK-DC-SIGN and from passage one in U937-DC-SIGN was isolated for sequencing. The E217A mutation was retained and no compensatory mutations were introduced (data not shown).

To elucidate the molecular mechanism of attenuation, we over-expressed human IFIT1, 2, 3, or 5 in HEK-DC-SIGN cells. The cells were infected with WT or mutant DENV-2 and assessed for the number of infected cells by flow cytometry (Fig. 5C). The WT virus infection was not affected, whereas E217A mutants were significantly inhibited by IFIT1, but not IFIT2, 3, or 5. However, IFIT1 over-expression did not completely block E217A infection nor did it affect virus output from the infected cells (Fig. 5D), suggesting that other IFN-mediated signals are involved in the response against DENV. Both mutant and WT virus show similar growth kinetics in untreated cells (Fig. 5E). We currently don’t know why the mutant virus is attenuated in Vero cells but not in HEK-DC-SIGN since both lines are deficient in IFN production. It should be noted that the maximum antiviral effect of IFITs

### Table 3. Reciprocal neutralizing antibody titer in RMs immunized with DENV-2 E217A.

| E217A dose (log10 PFU) | Monkey   | Gender | Reciprocal neutralizing antibody titer (PRNT50) |
|------------------------|----------|--------|-------------------------------------------------|
|                        |          |        | Day post immunization | Day post challenge* |
|                        |          |        | −1 | 15 | 30 | 15 | 30 |
| 5.0                    | R0319    | M      | <10 | 33 | 106 | 218 | 597 |
| 5.0                    | R0212    | F      | <10 | 122 | 90  | 400 | 378 |
| 5.0                    | R0105    | M      | <10 | 55  | 170 | 339 | 348 |
| 5.0                    | R0942    | F      | <10 | 87  | 122 | 187 | 301 |
| GMT                    |          |        |     | 66  | 119 | 273 | 392 |
| 4.0                    | R0055    | M      | <10 | 46  | 447 | 411 | 386 |
| 4.0                    | R0482    | F      | <10 | 31  | 283 | 400 | 371 |
| 4.0                    | R0098    | F      | <10 | 29  | 80  | 190 | 405 |
| GMT                    |          |        |     | 35  | 216 | 315 | 387 |
| 3.0                    | R0198    | F      | <10 | 56  | 77  | 344 | 534 |
| 3.0                    | R0195    | M      | <10 | 17  | 154 | 597 | 542 |
| 3.0                    | R0200    | F      | <10 | 15  | 66  | 406 | 640 |
| GMT                    |          |        |     | 24  | 92  | 437 | 570 |

*All animals were challenged with 1 × 10⁶ PFU of WT DENV-2 on day 64 post-immunization.

doi:10.1371/journal.ppat.1003521.t003

### Table 4. Viremia in E217A-immunized RMs after challenge with wild-type DENV-2*.

| Group (log10 PFU) | Monkey   | Dose (log10 PFU) | Viremia (log10 PFU/ml) by post challenge day | Peak titer (SD) | Duration days (SD) |
|-------------------|----------|------------------|---------------------------------------------|----------------|-------------------|
|                   |          |                  | 1 2 3 4 5 6 7 8 9                          |                |                   |
| E217A             | R0319    | 5                | 0 0 0 0 0 0 0 0 0                          |                |                   |
| 5.0               | R0212    | 5                | 0 0 0 0 0 0 0 0 0                          |                |                   |
| R0105             | 5        | 0 0 0 0 0 0 0 0 0 |                |                |                   |
| R0942             | 5        | 0 0 0 0 0 0 0 0 0 |                |                |                   |
| GMT               |          |                  |                                             |                |                   |
| E217A             | R0055    | 5                | 0 0 0 0 0 0 0 0 0                          |                |                   |
| 4.0               | R0482    | 5                | 0 0 0 0 0 0 0 0 0                          |                |                   |
| R0098             | 5        | 0 0 0 0 0 0 0 0 0 |                |                |                   |
| GMT               |          |                  |                                             |                |                   |
| E217A             | R0198    | 5                | 0 0 0 0 0 0 0 0 0                          |                |                   |
| 3.0               | R0195    | 5                | 0 0 0 0 0 0 0 0 0                          |                |                   |
| R0200             | 5        | 0 0 0 0 0 0 0 0 0 |                |                |                   |
| PBS               | R0522    | 5                | 1.9 1.7 0 0 0 2.3 1.6 0 0                 | 2.5(0.2)       | 4.8(0.5)          |
| R0342             | 5        | 1.6 2.8 1.7 2.4 2.1 0 0 0 0                 | 2.5(0.2)       | 4.8(0.5)          |
| R1751             | 5        | 0 0 1.5 2.3 1.7 1.9 2.4 0 0                 | 2.5(0.2)       | 4.8(0.5)          |
| R0351             | 5        | 0 2.0 2.0 2.6 2.4 1.6 0 0 0                 | 2.5(0.2)       | 4.8(0.5)          |

*Animals were challenged with 1 × 10⁶ PFU of WT DENV-2 on day 64 post-immunization.

doi:10.1371/journal.ppat.1003521.t004
could be underestimated due to the low transfection efficiency (30–50%) of the IFIT-expressing plasmids.

Inability of 2'-O-MTase mutant virus to infect the *Ae. aegypti* vector decreases the risk of mutant virus transmission

We compared the effect of 2'-O-MTase mutation on viral fitness in mosquito *Ae. aegypti*, the natural transmission vector for DENV. The mosquitoes were fed with blood containing WT or E217A. After the mosquitoes were fed at a titer of $1 \times 10^5$ PFU/ml, significant differences in oral infection and dissemination between the WT and mutant viruses were observed 15 days post-infection (Table 5). The WT virus infected 29% of mosquitoes at the highest titer ($1 \times 10^5$ PFU/ml), but only 1–6% of mosquitoes at lower titers ($1 \times 10^3$ and $1 \times 10^4$ PFU/ml). When orally fed with $1 \times 10^5$ PFU/ml WT virus, approximately 10% of mosquitoes were infected after 9; the WT virus disseminated in 24% of the mosquitoes (Table 5). When fed with $1 \times 10^3$ and $1 \times 10^4$ PFU/ml WT virus, the dissemination rates reached 1–4%. In contrast, the mutant virus was unable to infect the *Ae. aegypti* and, subsequently, no dissemination was observed for all titers (Table 5).

To examine whether the E217A mutant could replicate *in vivo*, we intra-thoracically inoculated the WT and mutant viruses into *Ae. aegypti* mosquitoes. Intra-thoracic inoculation bypasses the mosquito midgut, which is the key barrier to establish infection during natural feeding route. Both WT and mutant viruses reached 100% infection rate upon intra-thoracic inoculation. The mean genome copy number reached $4.6 \times 10^9$ and $6.2 \times 10^9$, respectively (Supplementary Fig. S6). The genome copy number of the WT virus was approximately 35% higher than that of the mutant virus ($p = 0.1054$). Overall, the results demonstrate that the 2'-O-MTase mutant virus is compromised in vector fitness.

Discussion

Various dengue vaccine strategies are currently under development, including live attenuated virus, subunit vaccines, chimeric viruses, and DNA vaccines [36,37]. The YFV 17D-based chimeric dengue vaccine developed by Sanofi-Pasteur is the most advanced in clinical testing [38,39]. The establishment of reverse genetic manipulation of DENV has greatly facilitated the generation of promising vaccine candidates [36,38]. The recent progress in understanding the mechanism of attenuation of 2'-O-MTase mutant flaviviruses has provided a novel approach for vaccine and antiviral development [40]. Here we show in a proof-of-concept study that MTase mutant E216A DENV-1 and E217A DENV-2 strains are stable in vitro, and safe and immunogenic in vivo. Importantly, enhancement of infection was not observed after heterologous infection of immunized mice. The fear in a clinical...
setting is that sub-neutralizing titers of antibodies could enhance infections, even though this has so far not happened in the context of vaccine trials in humans [41]. A commonly used approach to address ADE in vitro is to infect K562 cells in the presence of antibodies. Virus alone is not able to infect K562 cells efficiently, whereas virus-antibody immune complexes bind to K562 cells via Fc receptors (FcγR’s), assisting the internalization of the virus and infection of the cells. We found that K562 cells could be infected in the presence of serum from immunized mice and monkeys at dilutions that were approximately 50% neutralizing in the U937-DC-SIGN system [Supplementary Fig. S3 and S4]. This is in line with a previous report, which found that even strongly neutralizing antibodies are enhancing at concentrations that are close to the 50% neutralizing titer [42]. Clinically relevant ADE would be expected at sub-neutralizing titers and only after heterologous infection, and this was not observed in our experiments. A caveat of the K562 system is that the cells do not express inhibitory FcγRIIb, which is present on human target cells (dendritic cells and macrophages) and which negatively regulates ADE [43,44]. Physiological amounts of complement, another negative regulator of ADE, are also not taken into account [45]. In summary, while the K562 assays done here did not show more ADE for the WT virus, suggesting that DENV E217A mutant to IFN-β in vitro, we cannot explain fully why the 2′-O-MTase mutant virus was attenuated (10-fold lower virus titer compared to WT virus) in AG129 mice, which are unable to respond to IFN-signals. It is likely that pattern recognition receptors and downstream pathways activated by the mutant virus trigger antiviral defense mechanisms in an IFN-dependent and IFN-independent manner.

Whether the balance between low virulence and high immunogenicity is achieved in humans by 2′-O-MTase mutants remains to be elucidated. Our studies in human HEK293 cells show increased susceptibility of DENV2 E217A mutant to IFN-β in vitro, suggesting that DENV E217A mutants will be attenuated in humans as well. In the monkey immunization experiments, one monkey out of four in the high dose group experienced peak viremia of about 100 PFU, which is comparable to other live attenuated vaccine candidates [51]. Indeed, weak replication of the vaccine approach is desirable in order to induce a strong protective cellular immune response. Replication should be restricted enough to preclude onset of illness, whereas sub-clinical symptoms such as mild rash, transient leukopenia, and mildly elevated liver enzyme values are generally accepted [52–54]. Furthermore, studies with murine hepatitis virus have shown that MTase mutants are highly attenuated in its natural host, induce IFN, which could further induce the immunogenicity of a vaccine, and are genetically stable in vivo [15]. Moreover, the replication level of WNV 2′-O-MTase mutant in mice was largely decreased in the spleen, serum, or brain in comparison with the WT WNV infection. Intracranial inoculation of 1x10⁶ PFU of 2′-O-MTase mutant WNV did not cause any mortality and morbidity in mice, demonstrating the safety of this vaccine approach [14]. Taken together, these evidences demonstrate the safety and immunogenicity of the MTase-mutant vaccine approach. We are currently working on the tetravalent formulation to develop the strategy towards a clinical application.

Table 5. Ae. aegypti susceptibility according to virus type and titer.

| Virus          | Titer (log10 PFU/ml) | Infected/total female mosquitoes (%) | \(\chi^2\) | d.f | P-Value     | Disseminated/total female mosquitoes (\%)(c) | \(\chi^2\) | d.f | P-Value     |
|----------------|----------------------|--------------------------------------|---------|-----|------------|------------------------------------------|---------|-----|------------|
| WT             | 5                    | 24/82 (29%)                          | 0.043   | 2   | 0.817      | 20/82 (24%)                             | 1.472   | 2   | 0.479      |
| 4              | 1/72 (1%)            | 2.305                                | 0.3159  | 1/72 | 0.047      | 1/72 (1%)                              | 2.305   | 2   | 0.316      |
| 3              | 3/53 (6%)            | 3.151                                | 0.2069  | 3/53 | 0.442      | 2/53 (4%)                              | 1.725   | 2   | 0.422      |
| E217A          | 5                    | 0/47 (0%)                            | n/a     | 2   | n/a        | 0/47 (0%)                              | 0/47    | 0   | n/a        |
| 4              | 0/40 (0%)            | 2/40 (0%)                            | 1/72    | 0   | n/a        | 2/40 (0%)                              | 0/40    | 0   | n/a        |
| 3              | 0/60 (0%)            | 2/60 (0%)                            | n/a     | 2   | n/a        | 0/60 (0%)                              | 0/60    | 0   | n/a        |

*aInfected: presence of virus in abdomen.

*bDisseminated: presence of virus in thorax.

doi:10.1371/journal.ppat.1003521.005
Materials and Methods

Ethics statement

All experimental procedures involving Rhesus Monkeys were approved by and carried out in strict accordance with the guidelines of the Animal Experiment Committee of State Key Laboratory of Pathogen and Biosecurity, Beijing, China. All procedures were performed under sodium pentobarbital anesthesia by trained technicians and all efforts were made to ameliorate the welfare and to minimize animal suffering in accordance with the “Weatherall report for the use of non-human primates” recommendations.

The mouse experiments were conducted according to the rules and guidelines of the Agri-Food and Veterinary Authority (AVA) and the National Advisory Committee for Laboratory Animal Research (NACLR), Singapore. The experiments were reviewed and approved by the Institutional review board of Biological Resource Center, Singapore (IACUC protocols 90474 and 100536).

Cells

BHK-21, C6/36, and HEK-293 were purchased from the American type culture collection (http://www.atcc.org). HEK-293 and U937 cells expressing DC-SIGN were obtained by lentiviral transfection and subsequent cell sorting. All cells were maintained in minimal essential medium supplemented with fetal bovine serum (5%–10%).

Recombinant MTase preparation and methylation assays

WT MTases representing the N-terminal 262 and 296 amino acids of DENV-1 and -2 NS5, respectively, were cloned, expressed, and purified as reported previously [11]. Mutagenesis of MTase was performed using QuikChange II XL site-directed mutagenesis kit (Stratagene). The complete sequence of each mutant MTase was verified by DNA sequencing. N7- and 2’-O-methylation assays were performed as described before [11].

Preparation and characterization of recombinant DENV

Full-length infectious cDNA clones of DENV-1 (Western Pacific 74 strain) and DENV-2 (TSV01 strain) [55,56] were used to generate WT and mutant viruses. A standard mutagenesis protocol was used to engineer mutations into the MTase region as reported previously [11]. The protocols for in vitro transcription, RNA transfection, IFA, plaque assay, and growth kinetics were reported previously [23]. Strain D2Y96P was described previously [34].

Mice

Female or male 6–8 week old IFN α/β/γ receptor deficient mice (AG129) were purchased from B&K Universal Limited with permission from Dr. M. Aguet (ISREC, School of Life Sciences Ecole Polytechnique Fédérale (EPFL)). IFN α/β receptor deficient mice (IFNAR) on a C57BL/6 background were provided by Prof. Ulrich Kalinke [33]. All mice were bred and kept under specific pathogen-free conditions at the Biomedical Resource Centre, Singapore. For immunization, BHK-21 derived mutant and WT viruses were used. For challenge experiments DENV produced in C6/36 cells was used.

Rhesus monkey study

Fourteen RMs, weighing from 3.4 to 5.0 kg, were pre-screened negative for IgG antibodies against DENV and JEV by indirect immunofluorescence assay. Animals were randomly divided into four groups and inoculated subcutaneously (s.c.) in the deltoid region of left arm with 0.5 ml of DENV-2 E217A dilutions containing 5.0, 4.0, 3.0 log10 PFU, respectively. Animals in the control group received PBS. Blood was collected from each RM daily post immunization for 10 days to detect viremia. For neutralizing antibody tests, blood was taken before immunization (day –1) and on days 15 and 30 post-immunization. On day 64 post-immunization, all immunized animals including the PBS-treated control animals were challenged by s.c. inoculation of 0.5 ml containing 5 log10 PFU of DENV-2 (TSV-01). For the following 9 days, blood was collected for determination of viremia. Neutralizing antibody levels in serum were measured by the standard 50% plaque reduction neutralization test (PRNT50) on days 15 and 30 post-challenge, respectively.

Determination of viremia in monkey sera

Viremia in serum samples was determined by plaque assay in BHK-21 cell monolayers in 12-well plates. Undiluted serum or serial 10-fold dilutions of serum were inoculated onto BHK cells. After 1 h of adsorption at 37°C, wells were overlaid with 1 ml of DMEM supplemented with 2% FBS and 1% agarose. Plates were incubated for 4 days at 37°C in 5% CO2. Monolayers were fixed by addition of 1 ml of 4% formalin solution to the overlay medium. After 1 h of fixation at room temperature, the fixative was removed, wells were washed with water, and monolayers were stained with 1% crystal violet in 70% methanol. Plaques were counted, and titers were expressed as PFU/ml.

Plaque reduction neutralization test

For determination of dengue virus-neutralizing antibody titers, serial twofold dilutions of serum (starting at a dilution of 1:10) were mixed with equal volumes of a suspension of ~500 PFU of DENV-2 TSV01/ml. The serum-virus mixtures were incubated at 37°C for 1 h and tested (0.2 ml/well) for concentration of infectious virus using the plaque assay described above. The neutralizing titer was defined as the lowest serum dilution at which the infectious virus concentration was reduced by 50% from the concentration found when virus was incubated with culture medium.

IFN pretreatment and IFIT overexpression

Cells were seeded at 1×10^5 per well in a 24-well plate and treated 24 hours prior to infection with medium or varying concentrations of human recombinant IFN-β (Immunotools). Cells were then infected at an MOI of 1 with WT or MTase mutant virus (TSV01), respectively, incubated for 72 hours and harvested and processed for flow cytometry as described. Supernatants were collected for plaque assay.

IFIT expression plasmids were a kind gift from A. Pichlmair (14). For IFIT overexpression cells were seeded at 1×10^5 per well in a 6-well plate. 24 hours later cells were transfected using 293fectin according to manufacturer’s protocol. One day post transfection cells were trypsinized and seeded in a 24-well plate at 1×10^5 per well. After 24 hours of incubation cells were infected and analyzed as described previously. Transfection rate was 30–50% judged by parallel experiments with GFP expression plasmid.

Detection of infection by flow cytometry, ADE assay and flow cytometry-based neutralization assay

To determine the percentage of infected cells, cells were harvested, washed in PBS and fixed and permeabilized with Cytofix/ Cytoperm (BD). Intracellular dengue E protein was stained with antibody 4G2 conjugated to Alexa 647 and fluorescent cells were measured by flow cytometry.
For the assessment of ADE, 4G2 or serum/plasma was serially diluted and a constant amount of virus was added. The antibody-virus mixture was incubated at 37 °C for 30 min and then 50 μl of the mixture was added to 23'000 K562 cells per 96-plate well (MOI 0.5–1). After 2 h of infection 150 μl RPMI medium containing FCS was added. After 2.5 days of incubation the infected cells were fixed and stained intracellularly with 4G2-Alexa 647. The percentage of infected cells was quantified by flow cytometry.

For the measurement of neutralization, 4G2 or heat-inactivated serum/plasma was serially diluted and a constant amount of virus was added. The antibody-virus mixture was incubated at 37 °C for 30 min and then 50 μl of the mixture was added to 200,000 U937 cells (ATCC) stably transfected with human DC-SIGN (MOI 0.1–1). After 2 h of infection 150 μl RPMI medium containing FCS was added. After incubation over night the infected cells were fixed and stained intracellularly with 4G2-Alexa 647. The percentage of infected cells was quantified by flow cytometry and data were analyzed with GraphPad Prism software for the calculation of the NT50.

### T cell re-stimulation

Spleens were harvested at day 7 after infection and single cell suspensions were incubated with live virus or a pool of the following peptides: N81B59-66, N81B99-107 and N85237-243 [32] overnight. Brefeldin (Biolegend) was added for 5 h before cells were washed and stained with antibodies CD4-APC, CD8-PerCPeCy5.5 and IFN-γ-PE-Cy7 (Biolegend). Cells were acquired on a FACScanCantoII (BectonDickinson) and data were analyzed with FlowJo (Treestar ltd.).

### IgG ELISA

96-well polystyrene plates were coated with concentrated, heat inactivated dengue virus. Plates were incubated overnight at 4 °C. Before use, plates were washed three times in PBS (pH 7.2) containing 0.05% Tween-20 (PBS-T). Non-specific binding was blocked with 2% non-fat dry milk diluted in PBS (PBS-M) for 2 h at room temperature (RT). After washing, sera were diluted 1:50 in PBS-M, heat inactivated for 1 hour at 55 °C and threefold serial dilutions were added to the wells. Plates were incubated for 1 h at RT, followed by three washes with PBS-T. Peroxidase-conjugated rabbit anti-mouse IgG, in PBS-M was added, followed by 1 h of incubation at RT and three additional washes with PBS-T. TMB was used as the enzyme substrate. The reaction was stopped with 1 M HCl and the optical densities were read at 450 nm using an automatic ELISA plate reader. Endpoint titers were defined as the lowest dilution of plasma in which binding was twofold greater than the mean binding observed with the negative controls.

### Vector competence experiments

Vector competence experiments were performed using a colony of Aedes aegypti mosquitoes in which 10% of the population is derived from field obtained eggs each month. Batches of 50–75 female mosquitoes, aged 5–7 days were fed with pig blood containing WT or MTase mutant DENV-2 at titers of 5, 4, and 3 log 10 PFU/ml. Fully engorged mosquitoes were held at 27 °C, 80% relative humidity, and 12 h photoperiod for 15 days, after which the abdomens was separated from the thorax and homogenized. Homogenates were inoculated into Vero cell culture. After culturing the inoculated cells for 5 days, viral infection was assayed using an indirect fluorescent antibody test (IFA). Antibody 6B6C-1 against flavivirus group E protein (at 1:10 dilution; provided by the USA CDC as a mouse hybridoma) and an anti-mouse antibody conjugated with FITC were used as a primary and secondary antibody, respectively. Positive fluorescence determinations were performed manually using an inverted fluorescent microscope (Olympus IX71). Chi-square and contingency table statistical tests were performed to detail heterogeneity in vector competence within/between WT and mutant viruses.

Intra-thoracic inoculation of 0.17 μl of WT DENV-2 and E217A at a titer of 10^9 PFU/ml was performed using 10 female mosquitoes each. Following inoculation, mosquitoes were held for seven days under the same conditions as described above. Mosquitoes were then killed by freezing and homogenized. Viral RNA was quantified by real-time qRT-PCR using primers and methods reported previously [57]. Briefly, whole mosquito homogenate viral RNA was extracted using QIAamp Viral RNA Mini Kit (Qiagen). qRT-PCR was completed using Invitrogen Super-Script III Platinum One-Step qRT-PCR mix (without ROX) and GFP96 Real-Time PCR Detection System (BioRad). Cycling parameters performed were 50 °C for 30 min, 95 °C for 2 min, followed by 45 cycles of 95 °C for 10 sec, 60 °C for 30 sec. A two-tailed unpaired t-test was performed to determine the statistic difference between the mean genomic equivalents calculated for WT and mutant viruses.

### Deep sequencing

Virus was isolated from mouse serum with Qiagen Viral RNA extraction Kit. Fifty ng of viral RNA were used to prepare cDNA libraries using the Illumina TruSeq RNA sample preparation kit according to manufacturer’s protocol. The only protocol modification was the removal of the mRNA enrichment step. The cDNA libraries were sequenced as a multiplex in a single lane of an Illumina HiSeq2000 (Next Generation Sequencing Core facility, Genomic Institute of Singapore). One to 2 million 50 bp paired-end reads were generated for each virus.

Wild-type and mutant virus samples were mapped to their respective reference genomes using Bowtie 2 [58]. Mapping statistics and genotype calls were made with SAMtools [59]. Data analysis was performed in Pipeline Pilot (http://www.accelrys.com). At least two reads with an alternate base at a given position were defined as a SNP.

### Statistical analysis

Statistical tests were performed with GraphPad Prism software, using students t test, two-way ANOVA or Chi-square and contingency table statistical tests as indicated in the figure legends.

### Supporting Information

Figure S1 Genetic stability of the E216/E217A mutation in vitro and in vivo. Indicated mutant virus were passaged 10 times on Vero cells (a) or HEK-DC-SIGN cells (b), c) Mice were infected with 2.75 x 10^3 PFU of the indicated virus and viral RNA was isolated from plasma three days post infection. Shown are sequences of RT-PCR products from the mutated region. The mutation sites are indicated with red boxes. (TIF)

Figure S2 Characterization of DENV-1 MTase. (a) SDS-PAGE analysis. DENV-1 and DENV-2 MTases were expressed and purified [23]. The recombinant proteins were analyzed on a 12% SDS-PAGE. DENV-1 and DENV-2 MTases contained the N-terminal 262 and 296 amino acids of NS5 protein, respectively. Molecular masses of protein markers are labeled. Note that amino acid E216 of DENV-1 MTase is equivalent to amino acid E217 of DENV-2-MTase. (b) Effects of E216A and K61+E216A mutations of MTase on N7- and 2'-O methylation activities. Relative methylation activities were indicated below the TLC images with red boxes. (TIF)
BH2-21 cells were transfected with equal amounts of WT and mutant genome-length RNAs of DENV-2. The cells were examined for viral E protein expression at indicated days post transfection. (d) Plaque morphology. WT and mutant DENV-1 recovered from viral RNA-transfected cells (passage 0), as well as the viruses after cultivating on Vero cells for 10 rounds (passage 10) were analyzed by plaque assays. (e) Growth kinetics. Vero and C3/36 cells were infected with WT and mutant DENV-1 at an MOI of 0.1, and measured for viral yields at indicated time points. Average results of three experiments are presented. (TIF)

Figure S3 Neutralization and ADE assay with AG129 mouse plasma. Plasma from AG129 mice was analyzed 30 days after immunization with mutant or wild-type DENV. Upper graphs in panels a, b and c show ADE assays using K562 cells and lower graphs show the corresponding neutralization assay using U937-DENV-2. Groups of mice were immunized with a) DENV1 E216A, DENV-1 WT, DENV-1 E216A and DENV2 E216A combined or PBS; b) DENV-2 E217A or DENV-2 WT. c) Antibody 4G2 was used as a control technical. Symbols are means±SEM of three sera per group, tested in duplicate. The shown experiment is representative for one of two. The mean ± SD of the two independent experiments (n = 3–4 per group) are shown in Table 1. (TIF)

Figure S4 Neutralization and ADE assay with NHP serum. The serum of three monkeys per group was analyzed for ADE activity. Sera from day 5 after challenge in PBS animals (day 5 post infection) or 3 days after challenge in animals which had been immunized with E217A 64 days earlier (day 5 post challenge). a) K562 cells were infected with DENV-1 or DENV-2 in the presence of serum diluted as indicated in the x axes. Symbols are means±SEM of three sera per group from two independent ADE assays testing the sera in duplicate each. b) The same sera were tested for neutralization by using U937-DENV-2 as target cells. Symbols are means±SD of three sera per group, tested in duplicate each. c and d) 4G2 antibody was used as a control technical for the infection of K562 cells (c) or U937-DENV-1 cells (d). Symbols are means±SD of duplicate values. (TIF)

References
1. Farrar J, Focks D, Gubler D, Barrera R, Guzman MG, et al. (2007) Towards a global dengue research agenda. Trop Med Int Health 12: 695–699.
2. Gubler DJ (2002) The global emergence/resurgence of arboviral diseases as public health problems. Arch Med Res 3: 330–342.
3. Alvarez M, Rodriguez-Roque B, Larioso L, Vazquez S, Morier L, et al. (2006) Dengue hemorrhagic Fever caused by sequential dengue 1–3 virus infections over a long time interval. Havana epidemic, 2001–2002. Am J Trop Med Hyg 75: 1113–1117.
4. Halstead SB (2007) Dengue. Lancet 368:1644–1652.
5. Beatty ME, Beutels P, Meltzer MI, Shepard DS, Hombach J, et al. (2011) Health economics of dengue: a systematic literature review and expert panel’s assessment. Trop Med Int Health 12: 695–699.
6. Pulendran B, Ahmed R (2011) Immunological mechanisms of vaccination. Nat Immunol 12: 509–517.
7. Blaney JE, Jr., Matro JM, Murphy BR, Whitehead SS (2005) Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys. J Virol 79: 5316–5328.
8. Gunther VJ, Putnak R, Eckels KH, Mammen DP, Scherer JM, et al. (2011) A human challenge model for dengue infection reveals a possible protective role for sustained interferon gamma levels during the acute phase of illness. Vaccine 29: 3895–3904.
9. Hanley KA, Manicourt DR, Maniopon GG, Hanson CT, Whitehead SS, et al. (2004) Introduction of mutations into the non-structural genes or 3’ untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunity. Vaccine 22: 3440–3448.
10. Tan BH, Fu J, Sugrue RJ, Yap EH, Chan YC, et al. (1996) Recombinant dengue type 1 virus NS5 protein expressed in Escherichia coli exhibits RNA-dependent RNA polymerase activity. Virology 216: 317–325.
11. Ray D, Shah A, Tilgner M, Guo Y, Zhao Y, et al. (2006) West Nile virus 5’-cap structure is formed by sequential guanine N-7 and ribose 2'-O-methylations by nonstructural protein 5. J Virol 80: 8362–8370.
12. Egloff MP, Benzroth D, Schubert M, Schubert J, Canard B (2002) A monoclonal antibody directed against a conserved epitope of flavivirus NS5 capsid protein neutralizes all four dengue serotypes. J Virol 76: 9097–9102.
13. Dong H, Chang DC, Hua MH, Lam SP, Chien YH, et al. (2012) 2'-O-methylation of viral mRNA cap evades host restriction by IFIT family members. PLoS Pathog 8: e1002642.
14. Daffis S, Szterjer KJ, Schriewer J, Li J, Youn S, et al. (2010) 2'-O-methylation of the viral mRNA cap evades host restriction by IFIT family members. Nature 460: 452–456.
15. Zuo R, Gervante-Barragan L, Habjan M, Maier R, Neumann BW, et al. (2011) Ribose 2'-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5. Nat Immunol 12: 137–143.
16. Chang TH, Liao CL, Liu YL (2006) Flavivirus induces interferon-beta gene expression through a pathway involving IRF-1-dependent IRF-3 and PISK-dependent NF-kappaB activation. Microbes Infect 8: 157–171.
17. Loo YM, Fornek J, Crochet N, Rajva G, Perwitasari O, et al. (2008) Distinct IRF-1 and MDA5 signaling by RNA viruses in innate immunity. J Virol 82: 335–345.
18. Pichlmair A, Lassnig C, Ebeler GA, Gerna MW, Bannun M, et al. (2011) IFIT1 is an antiviral protein that recognizes 5'-triphosphate RNA. Nat Immunol 12: 624–630.
19. Fensterl V, Sen GC (2011) The ISG56/IFIT1 gene family. J Interferon Cytokine Res 31: 71–78.

20. Guo J, Hui DJ, Merrick WC, Sen GC (2000) A new pathway of translational regulation mediated by eukaryotic initiation factor 3. EMBO J 19: 6891–6899.

21. Liu C, Wang X, Wei B, Shen J, Wang Q (2011) IFN-induced TPR protein IFIT3 potentiates antiviral signaling by bridging MAVS and TBK1. J Immunol 187: 2559–2568.

22. Dong H, Zhang B, Shi PY (2008) Flavivirus methyltransferase: a novel antiviral target. Antiviral Res 79: 120–127.

23. Dong H, Chang DC, Xie X, Tob YX, Chung KY, et al. (2010) Biochemical and genetic characterization of dengue virus methyltransferase. Virology 405: 568–578.

24. Tassaneetrithep B, Burgess TH, Granelli-Piperno A, Trumpfheller C, Finke J, et al. (2008) Flavivirus methyltransferase: a novel antiviral target. Antiviral Res 79: 120–127.

25. Slusher BS, Pierson TC, Noura H, LeBlanc JT, Ohshiro S, et al. (2007) The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe 1: 135–145.

26. Anderson KB, Gibbons RV, Edelman R, Eckels KH, Putnak RJ, et al. (2011) Long-term safety assessment of live attenuated tetravalent dengue vaccines: Deliberations from a WHO technical consultation. Vaccine 31: 2603–9.

27. Coller BA, Clements DE (2011) Dengue vaccines: progress and challenges. Curr Opin Immunol 23: 391–398.

28. Schul W, Liu W, Xu HY, Flamand M, Vasudevan SG (2007) A dengue fever vaccine candidate. J Infect Dis 204: 442–450.

29. Kamphuis E, Junt T, Waibler Z, Forster R, Kalinke U (2006) Type I interferons and IFIT3 potentiates antiviral signaling by bridging MAVS and TBK1. J Immunol 177: 6567–6574.

30. Williams KL, Wahala WM, Orozco S, de Silva AM, Harris E (2012) Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo. Virology 429: 12–20.

31. Guirakhoo F, Weltzin R, Chambers TJ, Zhang ZX, Soike K, et al. (2000) Neutralizing antibodies after infection with dengue 1 virus. Emerg Infect Dis 13: 232–236.

32. Anderson KB, Gibbons RV, Edelman R, Eckels KH, Putnak RJ, et al. (2011) Interference and facilitation between dengue serotypes in a tetravalent live dengue virus vaccine candidate. J Infect Dis 204: 442–450.

33. Yauch LE, Zellweger RM, Kotturi MF, Qutubuddin A, Sidney J, et al. (2009) A novel strategy for blocking dengue virus-neutralizing monoclonal antibody enhancement of dengue disease in mice is prevented by Fc receptor IIB. J Clin Virol 46 Suppl 2: S20–24.

34. Chan KR, Zhang SL, Tan HC, Chan YK, Chow A, et al. (2011) Ligation of Fc receptor IIIb inhibits antibody-dependent enhancement of dengue virus infection. Proc Natl Acad Sci U S A 108: 12479–12484.

35. Sun W, Cunningham D, Wasserman SS, Perry J, Putnak JR, et al. (2009) Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine: randomized controlled phase I trial in the Philippines. Vaccine 29: 3863–3872.

36. Coller BA, Clements DE (2011) Dengue vaccines: progress and challenges. Curr Opin Immunol 23: 391–398.

37. Webster DP, Farrar J, Rowland-Jones S (2009) Progress towards a dengue vaccine. Lancet Infect Dis 9: 679–687.

38. Murphy BR, Whitehead SS (2011) Immune response to dengue virus and prospects for a vaccine. Annu Rev Immunol 29: 587–619.

39. Sabacharon A, Wallace D, Sirivichayakul C, Limkittikul K, Champvanich P, et al. (2012) Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 380: 1559–67.

40. Lim SP, Sonntag LS, Noble C, Nilar SH, Ng RH, et al. (2011) Small molecule inhibitors that selectively block dengue virus methyltransferase. J Biol Chem 286: 6233–6240.

41. Bents-Echill AD, Schmitz J, Edelman R, Durbin A, Roehrig JT, et al. (2013) Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo. Virology 429: 12–20.

42. Schul W, Orozco S, de Silva AM, Harris E (2012) Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo. Virology 429: 12–20.

43. Williams KL, Wahala WM, Orozco S, de Silva AM, Harris E (2012) Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo. Virology 429: 12–20.

44. Chan KR, Zhang SL, Tan HC, Chan YK, Chow A, et al. (2011) Ligation of Fc receptor IIIb inhibits antibody-dependent enhancement of dengue virus infection. Proc Natl Acad Sci U S A 108: 12479–12484.

45. Guirakhoo F, Weltzin R, Chambers TJ, Zhang ZX, Soike K, et al. (2000) Recombinant dengue vaccine (DENVax) formula-